Skip to main content
Top
Published in: BMC Medical Informatics and Decision Making 1/2007

Open Access 01-12-2007 | Research article

Can postponement of an adverse outcome be used to present risk reductions to a lay audience? A population survey

Authors: Rasmus Dahl, Dorte Gyrd-Hansen, Ivar Sønbø Kristiansen, Jørgen Nexøe, Jesper Bo Nielsen

Published in: BMC Medical Informatics and Decision Making | Issue 1/2007

Login to get access

Abstract

Background

For shared decision making doctors need to communicate the effectiveness of therapies such that patients can understand it and discriminate between small and large effects. Previous research indicates that patients have difficulties in understanding risk measures. This study aimed to test the hypothesis that lay people may be able to discriminate between therapies when their effectiveness is expressed in terms of postponement of an adverse disease event.

Methods

In 2004 a random sample of 1,367 non-institutionalized Danes aged 40+ was interviewed in person. The participants were asked for demographic information and asked to consider a hypothetical preventive drug treatment. The respondents were randomized to the magnitude of treatment effectiveness (heart attack postponement of 1 month, 6 months, 12 months, 2 years, 4 years and 8 years) and subsequently asked whether they would take such a therapy. They were also asked whether they had hypercholesterolemia or had experienced a heart attack.

Results

In total 58% of the respondents consented to the hypothetical treatment. The proportions accepting treatment were 39%, 52%, 56%, 64%, 67% and 73% when postponement was 1 month, 6 months, 12 months, 2 years, 4 years and 8 years respectively. Participants who thought that the effectiveness information was difficult to understand, were less likely to consent to therapy (p = 0.004).

Conclusion

Lay people can discriminate between levels of treatment effectiveness when they are presented in terms of postponement of an adverse event. The results indicate that such postponement is a comprehensible measure of effectiveness.
Literature
1.
go back to reference van Hout BA, Simoons ML: Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?. Eur Heart J. 2001, 22 (9): 751-61. 10.1053/euhj.2000.2308.CrossRefPubMed van Hout BA, Simoons ML: Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?. Eur Heart J. 2001, 22 (9): 751-61. 10.1053/euhj.2000.2308.CrossRefPubMed
2.
go back to reference Simons LA, Levis G, Simons J: Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust. 164 (4): 208-11. 1996 Feb 19 Simons LA, Levis G, Simons J: Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust. 164 (4): 208-11. 1996 Feb 19
3.
go back to reference Perrault S, Blais L, Lamarre D, Dragomir A, Berbiche D, lalonde L, laurier C, St-Maurice F, Collin J: Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol. 2005, 61 (9): 667-74. 10.1007/s00228-005-0980-z. Epub 2005 Oct 19CrossRef Perrault S, Blais L, Lamarre D, Dragomir A, Berbiche D, lalonde L, laurier C, St-Maurice F, Collin J: Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol. 2005, 61 (9): 667-74. 10.1007/s00228-005-0980-z. Epub 2005 Oct 19CrossRef
4.
go back to reference Edwards A, Elwyn G, Hood K, Atwell C, Robling M, Houston H, Kinnersley P, Russell I, Study Steering Group: Patient-based outcome results from a cluster randomized trial of shared decision making skill development and use of risk communication aids in general practice. Fam Pract. 2004, 21 (4): 347-354. 10.1093/fampra/cmh402.CrossRefPubMed Edwards A, Elwyn G, Hood K, Atwell C, Robling M, Houston H, Kinnersley P, Russell I, Study Steering Group: Patient-based outcome results from a cluster randomized trial of shared decision making skill development and use of risk communication aids in general practice. Fam Pract. 2004, 21 (4): 347-354. 10.1093/fampra/cmh402.CrossRefPubMed
5.
go back to reference Edwards A, Elwyn G, Wood F, Atwell C, Prior L, Houston H: Shared decision making and risk communication in practice: a qualitative study of GPs' experiences. Br J Gen Pract. 2005, 55 (510): 6-13.PubMedPubMedCentral Edwards A, Elwyn G, Wood F, Atwell C, Prior L, Houston H: Shared decision making and risk communication in practice: a qualitative study of GPs' experiences. Br J Gen Pract. 2005, 55 (510): 6-13.PubMedPubMedCentral
6.
go back to reference Cranney M, Walley T: Same information, different decisions: the influence of evidence on the management of hypertension in the elderly. Br J Gen Pract. 1996, 46 (412): 661-3.PubMedPubMedCentral Cranney M, Walley T: Same information, different decisions: the influence of evidence on the management of hypertension in the elderly. Br J Gen Pract. 1996, 46 (412): 661-3.PubMedPubMedCentral
7.
go back to reference Forrow L, Taylor WC, Arnold RM: Absolutely relative: how research results are summarized can affect treatment decisions. Am J Med. 1992, 92 (2): 121-4. 10.1016/0002-9343(92)90100-P.CrossRefPubMed Forrow L, Taylor WC, Arnold RM: Absolutely relative: how research results are summarized can affect treatment decisions. Am J Med. 1992, 92 (2): 121-4. 10.1016/0002-9343(92)90100-P.CrossRefPubMed
8.
go back to reference Hux JE, Naylor CD: Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment?. Med Decis Making. 1995, 15 (2): 152-7. 10.1177/0272989X9501500208.CrossRefPubMed Hux JE, Naylor CD: Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment?. Med Decis Making. 1995, 15 (2): 152-7. 10.1177/0272989X9501500208.CrossRefPubMed
9.
10.
go back to reference Halvorsen PA, Kristiansen IS: Decisions on drug therapies by numbers needed to treat: a randomized trial. Arch Intern Med. 2005, 165 (10): 1140-1146. 10.1001/archinte.165.10.1140.CrossRefPubMed Halvorsen PA, Kristiansen IS: Decisions on drug therapies by numbers needed to treat: a randomized trial. Arch Intern Med. 2005, 165 (10): 1140-1146. 10.1001/archinte.165.10.1140.CrossRefPubMed
11.
go back to reference Nexoe J, Kristiansen IS, Gyrd-Hansen D, Nielsen JB: Influence of number needed to treat, costs and outcome on preferences for a preventive drug. Fam Pract. 2005, 22 (1): 126-131. 10.1093/fampra/cmh706.CrossRefPubMed Nexoe J, Kristiansen IS, Gyrd-Hansen D, Nielsen JB: Influence of number needed to treat, costs and outcome on preferences for a preventive drug. Fam Pract. 2005, 22 (1): 126-131. 10.1093/fampra/cmh706.CrossRefPubMed
12.
go back to reference Sheridan SL, Pignone MP, Lewis CL: A randomized comparison of patients' understanding of number needed to treat and other common risk reduction formats. J Gen Intern Med. 2003, 18 (11): 884-92. 10.1046/j.1525-1497.2003.21102.x.CrossRefPubMedPubMedCentral Sheridan SL, Pignone MP, Lewis CL: A randomized comparison of patients' understanding of number needed to treat and other common risk reduction formats. J Gen Intern Med. 2003, 18 (11): 884-92. 10.1046/j.1525-1497.2003.21102.x.CrossRefPubMedPubMedCentral
13.
go back to reference Christensen PM, Brøsen K, Brixen K, Kristiansen IS: Expressing effects of osteoporosis interventions in terms of postponing of fractures. Eur J Clin Pharmacol. 2002, 58 (9): 629-33. 10.1007/s00228-002-0526-6. Epub 2002 Nov 9.CrossRefPubMed Christensen PM, Brøsen K, Brixen K, Kristiansen IS: Expressing effects of osteoporosis interventions in terms of postponing of fractures. Eur J Clin Pharmacol. 2002, 58 (9): 629-33. 10.1007/s00228-002-0526-6. Epub 2002 Nov 9.CrossRefPubMed
14.
go back to reference Christensen PM, Brosen K, Brixen K, Andersen M, Kristiansen IS: A randomized trial of laypersons' perception of the benefit of osteoporosis therapy: Number needed to treat versus postponement of hip fracture. Clin Ther. 2003, 25 (10): 2575-2585. 10.1016/S0149-2918(03)80318-1.CrossRefPubMed Christensen PM, Brosen K, Brixen K, Andersen M, Kristiansen IS: A randomized trial of laypersons' perception of the benefit of osteoporosis therapy: Number needed to treat versus postponement of hip fracture. Clin Ther. 2003, 25 (10): 2575-2585. 10.1016/S0149-2918(03)80318-1.CrossRefPubMed
15.
go back to reference Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344: 1383-9. 1994 Nov 19 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344: 1383-9. 1994 Nov 19
16.
go back to reference Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen T: Cost Effectiveness of Simvastatin Treatment to Lower Cholesterol Levels in Patients with Coronary Heart Disease. New Engl J Med. 1997, 336 (5): 332-6. 10.1056/NEJM199701303360503.CrossRefPubMed Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen T: Cost Effectiveness of Simvastatin Treatment to Lower Cholesterol Levels in Patients with Coronary Heart Disease. New Engl J Med. 1997, 336 (5): 332-6. 10.1056/NEJM199701303360503.CrossRefPubMed
17.
go back to reference Kristiansen IS, Gyrd-Hansen D, Nexoe J, Nielsen JB: Number needed to treat: easily understood and intuitively meaningful?. Theoretical considerations and a randomized trial. J Clin Epidemiol. 2002, 55 (9): 888-902. 10.1016/S0895-4356(02)00432-8.CrossRefPubMed Kristiansen IS, Gyrd-Hansen D, Nexoe J, Nielsen JB: Number needed to treat: easily understood and intuitively meaningful?. Theoretical considerations and a randomized trial. J Clin Epidemiol. 2002, 55 (9): 888-902. 10.1016/S0895-4356(02)00432-8.CrossRefPubMed
18.
go back to reference Naimark D, Naglie G, Detsky A: The meaning of life expectancy: what is a clinically significant gain?. J Gen Intern Med. 1994, 9 (12): 702-7. 10.1007/BF02599016.CrossRefPubMed Naimark D, Naglie G, Detsky A: The meaning of life expectancy: what is a clinically significant gain?. J Gen Intern Med. 1994, 9 (12): 702-7. 10.1007/BF02599016.CrossRefPubMed
19.
go back to reference Wright JC, Weinstein MC: Gains in life expectancy from medical interventions – standardizing data on outcomes. N Engl J Med. 339 (6): 380-6. 10.1056/NEJM199808063390606. 1998 Aug 6 Wright JC, Weinstein MC: Gains in life expectancy from medical interventions – standardizing data on outcomes. N Engl J Med. 339 (6): 380-6. 10.1056/NEJM199808063390606. 1998 Aug 6
Metadata
Title
Can postponement of an adverse outcome be used to present risk reductions to a lay audience? A population survey
Authors
Rasmus Dahl
Dorte Gyrd-Hansen
Ivar Sønbø Kristiansen
Jørgen Nexøe
Jesper Bo Nielsen
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Medical Informatics and Decision Making / Issue 1/2007
Electronic ISSN: 1472-6947
DOI
https://doi.org/10.1186/1472-6947-7-8

Other articles of this Issue 1/2007

BMC Medical Informatics and Decision Making 1/2007 Go to the issue